PHARMENA SA (PHR) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

FMCG

Market cap

PLN 34 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-14.34%

Price to Book

2.86

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2024)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.5%

6 Months

-12.65%

1 Year

-30.12%

2 Years

-52.1%

3 Years

-40.84%

4 Years

-66.63%

5 Years

-70.88%

PHARMENA SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-51.62%

EBIT Growth (5y)

9.46%

EBIT to Interest (avg)

-3.92

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

2.25

Tax Ratio

31.25%

Dividend Payout Ratio

32.71%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

23.51%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.18

EV to EBIT

-8.43

EV to EBITDA

-8.73

EV to Capital Employed

26.03

EV to Sales

26.58

PEG Ratio

Dividend Yield

ROCE (Latest)

-309.01%

ROE (Latest)

-14.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 44.44% vs -550.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-0.90",
          "chgp": "44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-30,954.50%",
          "val2": "-4,729.70%",
          "chgp": "-2,622.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs -98.03% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 619.23% vs -13.04% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-3.20",
          "chgp": "-15.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "27.00",
          "val2": "-5.20",
          "chgp": "619.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,448.20%",
          "val2": "-12,638.80%",
          "chgp": "-80.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Sep'24

Jun'24

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-0.70

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.50

-0.90

44.44%

Operating Profit Margin (Excl OI)

-30,954.50%

-4,729.70%

-2,622.48%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2024 is -100.00% vs 0.00% in Jun 2024

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 44.44% vs -550.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.30

Operating Profit (PBDIT) excl Other Income

-3.70

-3.20

-15.62%

Interest

0.50

0.70

-28.57%

Exceptional Items

-0.00

-0.20

100.00%

Consolidate Net Profit

27.00

-5.20

619.23%

Operating Profit Margin (Excl OI)

-13,448.20%

-12,638.80%

-80.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs -98.03% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 619.23% vs -13.04% in Dec 2022

All Annual Results

Company CV

About PHARMENA SA

PHARMENA SA

FMCG

Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.

Company Coordinates

Company Details

Ul. Wolczanska 178 , LODZ None : 90-530

Tel: 48 42 291337048 502 258387

http://www.pharmena.eu/

Registrar Details